Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tadalafil: a new agent for erectile dysfunction.

Gerald B Brock1

  • 1Department of Surgery, Division of Urology, St. Joseph's Health Centre, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada.

The Canadian Journal of Urology
|March 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies.

Sexual medicine·2025
Same author

Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis.

The lancet. Healthy longevity·2023
Same author

Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.

The lancet. Healthy longevity·2022
Same author

The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline.

The Journal of urology·2022
Same author

Shock Wave Therapy for Peyronie's Disease-Learning From the Past and Looking Into the Future.

The journal of sexual medicine·2022
Same author

Erectile dysfunction guideline: A missed opportunity?

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2021
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offers convenient and effective treatment for erectile dysfunction with a longer duration of action than other agents. Clinical trials confirm its safety and efficacy across various patient groups.

Area of Science:

  • Pharmacology
  • Urology
  • Clinical Medicine

Background:

  • Oral phosphodiesterase 5 (PDE5) inhibitors are first-line treatments for erectile dysfunction due to efficacy and safety.
  • Tadalafil is a novel PDE5 inhibitor with a distinct molecular structure and pharmacological profile.

Purpose of the Study:

  • To review clinical trials on tadalafil for erectile dysfunction.
  • To provide a comprehensive overview of tadalafil's efficacy and safety.

Main Methods:

  • Review of clinical trials involving tadalafil.
  • Analysis of efficacy and safety data from diverse patient populations.

Main Results:

  • Tadalafil demonstrates high efficacy in treating erectile dysfunction.

Related Experiment Videos

  • Tadalafil is associated with a favorable safety profile and low side effect rates.
  • Its longer duration of effectiveness distinguishes it from other PDE5 inhibitors.

    • Conclusions:

    • Tadalafil is a well-tolerated and effective oral treatment option for erectile dysfunction.
    • Its unique pharmacokinetic profile offers advantages in managing erectile dysfunction.
    • Guidelines recommend PDE5 inhibitors, including tadalafil, as a primary therapy.